Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 274

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Age and Outcome With Contemporary Thrombolytic Therapy: Results From the GUSTO-I Trial

White, Harvey D., Barbash, Gabriel I., Califf, Robert M., Simes, R. John, Granger, Christopher B., Weaver, W. Douglas, Kleiman, Neal S., Aylward, Philip E., Gore, Joel M., Vahanian, Alec, Lee, Kerry L., Ross, Allan M., Topol, Eric J.·1996·Circulation

Abstract

Background Elderly patients with acute myocardial infarction have much to gain from reperfusion with thrombolytic therapy but are also at increased risk of adverse events. We examined outcomes according to age of patients receiving thrombolysis in an international trial. Methods and Results Patients were randomized to streptokinase plus subcutaneous heparin, streptokinase plus intravenous heparin, accelerated tissue plasminogen activator (TPA) plus intravenous heparin, or streptokinase and TPA plus intravenous heparin. Clinical outcomes at 30 days (death, stroke, and nonfatal, disabling stroke) and 1-year mortality were summarized descriptively for patients aged <65 (n=24 708), 65 to 74 (n=11 201), 75 to 85 (n=4625), and >85 years (n=412) and assessed as continuous functions of age. Older patients had a higher-risk profile with regard to baseline clinical and angiographic characteristics. Mortality at 30 days increased markedly with age (3.0%, 9.5%, 19.6%, and 30.3% in the four groups, respectively), as did stroke, cardiogenic shock, bleeding, and reinfarction. Combined death or disabling stroke occurred less often with accelerated TPA in all but the oldest patients, who showed a weak trend toward a lower incidence with streptokinase plus subcutaneous heparin: odds ratio 1.13; 95% confidence interval 0.6, 2.1. Similarly, accelerated TPA treatment resulted in lower 1-year mortality in all but the oldest patients (47% TPA versus 40.3% streptokinase). Conclusions Lower mortality and greater net clinical benefit were seen with accelerated TPA in patients aged ≤85 years. Because data are limited for patients aged >85 years, the relative superiority of a given thrombolytic regimen cannot be determined. The interactions of stroke and mortality with newer thrombolytic strategies must be examined explicitly in older patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.94.8.1826

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 274

Metadata

Authors
White, H. D., Barbash, G. I., Califf, R. M., Simes, R. J., Granger, C. B., Weaver, W. D., Kleiman, N. S., Aylward, P. E., Gore, J. M., Vahanian, A., Lee, K. L., Ross, A. M., & Topol, E. J.
Venue
Circulation
Published
1996-10-15
Volume
94
Issue
8
Pages
1826-1833
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2037593193
Cited by
274
References
31
FWCI
8.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Age and Outcome With Contemporary Thrombolytic Therapy: Results From the GUSTO-I Trial. https://app.cochat.ai/papers/10.1161/01.cir.94.8.1826
The paper
White, H. D., Barbash, G. I., Califf, R. M., Simes, R. J., Granger, C. B., Weaver, W. D., Kleiman, N. S., Aylward, P. E., Gore, J. M., Vahanian, A., Lee, K. L., Ross, A. M., & Topol, E. J. (1996). Age and Outcome With Contemporary Thrombolytic Therapy: Results From the GUSTO-I Trial. Circulation. https://doi.org/10.1161/01.cir.94.8.1826

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.